231 related articles for article (PubMed ID: 25028381)
1. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies.
Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1600-6. PubMed ID: 25028381
[TBL] [Abstract][Full Text] [Related]
2. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission.
Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
Ann Rheum Dis; 2013 Oct; 72(10):1664-8. PubMed ID: 23117244
[TBL] [Abstract][Full Text] [Related]
3. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
4. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
Kaneko Y; Kondo H; Takeuchi T
J Rheumatol; 2013 Aug; 40(8):1254-8. PubMed ID: 23772077
[TBL] [Abstract][Full Text] [Related]
5. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness, Complications, and Costs of Rheumatoid Arthritis Treatment with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients.
Barnabe C; Zheng Y; Ohinmaa A; Crane L; White T; Hemmelgarn B; Kaplan GG; Martin L; Maksymowych WP
J Rheumatol; 2018 Oct; 45(10):1344-1352. PubMed ID: 29858236
[TBL] [Abstract][Full Text] [Related]
7. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada.
Foo J; Morel C; Bergman M; Baerwald C; Rodriguez-Heredia JM; Marshall A; Polanco-Sánchez C; Postema R
Rheumatol Int; 2019 Sep; 39(9):1621-1630. PubMed ID: 31240388
[TBL] [Abstract][Full Text] [Related]
8. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
9. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
[TBL] [Abstract][Full Text] [Related]
10. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
Mack ME; Hsia E; Aletaha D
Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
12. Remission in rheumatoid arthritis: a comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease activity index-5, a patient self-report disease activity index.
Rintelen B; Sautner J; Haindl P; Mai H; Brezinschek HP; Leeb BF
J Rheumatol; 2013 Apr; 40(4):394-400. PubMed ID: 23378466
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
Schoels M; Alasti F; Smolen JS; Aletaha D
Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
[TBL] [Abstract][Full Text] [Related]
14. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
Dhaon P; Das SK; Srivastava R; Dhakad U
Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
[TBL] [Abstract][Full Text] [Related]
15. The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.
Inanc N; Yilmaz-Oner S; Can M; Sokka T; Direskeneli H
J Rheumatol; 2014 Sep; 41(9):1755-60. PubMed ID: 25086073
[TBL] [Abstract][Full Text] [Related]
16. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
17. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
[TBL] [Abstract][Full Text] [Related]
18. Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis.
Carvalho PD; Ferreira RJO; Landewé R; Vega-Morales D; Salomon-Escoto K; Veale DJ; Chopra A; da Silva JAP; Machado PM
J Rheumatol; 2020 Jan; 47(1):20-27. PubMed ID: 31043552
[TBL] [Abstract][Full Text] [Related]
19. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.
Wang GY; Zhang SL; Wang XR; Feng M; Li C; An Y; Li XF; Wang LZ; Wang CH; Wang YF; Yang R; Yan HM; Wang GC; Lu X; Liu X; Zhu P; Chen LN; Jin HT; Liu JT; Guo HF; Chen HY; Xie JL; Wei P; Wang JX; Liu XY; Sun L; Cui LF; Shu R; Liu BL; Yu P; Zhang ZL; Li GT; Li ZB; Yang J; Li JF; Jia B; Zhang FX; Tao JM; Lin JY; Wei MQ; Liu XM; Ke D; Hu SX; Ye C; Han SL; Yang XY; Li H; Huang CB; Gao M; Lai B; Cheng YJ; Li XF; Song LJ; Yu XX; Wang AX; Wu LJ; Wang YH; He L; Sun WW; Gong L; Wang XY; Wang Y; Zhao Y; Li XX; Wang Y; Zhang Y; Su Y; Zhang CF; Mu R; Li ZG
Clin Rheumatol; 2015 Feb; 34(2):221-30. PubMed ID: 25413735
[TBL] [Abstract][Full Text] [Related]
20. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
